Rigel Pharmaceuticals
RIGL

$13.75

0.36%

Market Cap: $242M

About: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Employees: 147

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

16% more call options, than puts

Call options by funds: $4.28M | Put options by funds: $3.68M

12.35% less ownership

Funds ownership: 71.53% [Q1] → 59.18% (-12.35%) [Q2]

22% less funds holding

Funds holding: 116 [Q1] → 90 (-26) [Q2]

54% less capital invested

Capital invested by funds: $186M [Q1] → $85.4M (-$100M) [Q2]

67% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 39

96% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 72

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$57

315%

upside

Avg. target

$94

585%

upside

High target

$150

991%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis 35% 1-year accuracy 96 / 274 met price target	315%upside $57	Buy Reiterated	5 Sept 2024
HC Wainwright & Co. Joseph Pantginis 35% 1-year accuracy 96 / 274 met price target	315%upside $57	Buy Reiterated	3 Sept 2024
HC Wainwright & Co. Joseph Pantginis 35% 1-year accuracy 96 / 274 met price target	315%upside $57	Buy Maintained	9 Aug 2024
HC Wainwright & Co. Joseph Pantginis 35% 1-year accuracy 96 / 274 met price target	991%upside $150	Buy Reiterated	25 Jun 2024
HC Wainwright & Co. Joseph Pantginis 35% 1-year accuracy 96 / 274 met price target	991%upside $150	Buy Reiterated	17 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about RIGL published over the past 30 days

Rigel to Present at the 2024 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Sept. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Cantor Global Healthcare Conference on Thursday, September 19, at 9:10 am ET in New York, NY.

Rigel to Present at the 2024 Cantor Global Healthcare Conference

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

First trial in Rigel's multi-year strategic development alliance with MD Anderson Phase 1b/2 trial of decitabine and venetoclax in combination with Rigel's targeted mIDH1 inhibitor REZLIDHIA for patients with mIDH1 AML SOUTH SAN FRANCISCO, Calif. , Sept. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the first patient has been enrolled in a Phase 1b/2 triplet therapy trial of decitabine and venetoclax in combination with REZLIDHIA® (olutasidenib) in patients with mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML).

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan

Kissei gains exclusive rights to develop and commercialize olutasidenib in all current and potential indications in Japan, the Republic of Korea and Taiwan Rigel will receive an upfront cash payment of $10.0 million with the potential for up to $152.5 million in future development, regulatory, and commercial milestone payments Rigel to receive product transfer price payments in the mid-twenty to lower-thirty percent range based on tiered net sales for exclusive supply of REZLIDHIA SOUTH SAN FRANCISCO, Calif. , Sept. 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it has entered into an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd.

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan

Rigel to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Aug. 29, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September: 2024 Wells Fargo Healthcare Conference, Boston, MA Mr.

Rigel to Participate in Upcoming September Investor Conferences

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary Raul Rodriguez - President and CEO Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - CFO Conference Call Participants Yigal Nochomovitz - Citi Kristen Kluska - Cantor Joe Pantginis - H.C. Wainwright Operator Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the Second Quarter 2024.

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.40 per share a year ago.

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

Second quarter total revenue of $36.8 million, which includes TAVALISSE® net product sales of $26.4 million, REZLIDHIA® net product sales of $5.2 million and GAVRETO® net product sales of $1.9 million Successfully completed NDA transfer of GAVRETO for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer, with product available from Rigel beginning June 27, 2024 Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

Zacks Investment Research

Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Rigel (RIGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , July 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2024 financial results after market close on Tuesday, August 6, 2024.

Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Rigel Pharmaceuticals focuses on innovative therapeutics for hematological conditions and cancers, with FDA-approved products Tavalisse, Rezlidhia, and Gavreto targeting specific diseases. RIGL's pipeline also includes promising drug candidates like R289, targeting lower-risk myelodysplastic syndromes and other kinase-related diseases. Gavreto, recently acquired by RIGL, targets RET fusion-positive NSCLC and thyroid cancer, with significant potential for revenue growth.

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

See News Rankings